Dapagliflozin Patient Satisfaction Survey

Completed

Conditions studied: Diabetes Mellitus, Type 2

In brief

The purpose of this study is to evaluate the diabetes related treatment satisfaction for patients with type 2 diabetes mellitus

Key facts

Study ID

NCT02805283

Run by

AstraZeneca

People needed

653

Starts

2016-06-22

Expected to finish

2018-10-29

Last updated by the study team

2019-10-30

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• At least one pharmacy claim for dapagliflozin or dapagliflozin/metformin ER in the most recent month of pharmacy data and no pharmacy claims for an SGLT2 medication during the 6 months prior to sample identification.
• Evidence of T2D diagnosis.
• Age ≥18 as of the drug index date.
• 6 months of continuous enrollment in a commercial health plan with both pharmacy and medical benefits during the identification period through the patient interview sample identification date.
• Self-reported T2D diagnosis during the patient interview.

You may not qualify if…

• Patients with evidence of type 1 diabetes mellitus and unknown type
• Patients who are pregnant

Where it is running

• Reasearch Site — Eden Prairie, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.